Pinotbio
PrivateLast Round
VC Round
Oct 27, 2025
Est. Valuation
$79.55M
Total Funding Raised
$31.8M
Company Overview
Pinotbio is a biotechnology company that develops novel anticancer therapeutics and antibody-drug conjugate (ADC) platform technologies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Pinotbio Comparables
Compare Pinotbio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Novelty Nobility Inc. | 88% | |
| IntoCell Inc | 85% | |
| Aimed Bio Inc. | 84% |
Pinotbio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Oct 27, 2025 | ||||
| VC Round | Apr 21, 2023 | ||||
| Strategic | Oct 18, 2022 | ||||
| Strategic | Mar 22, 2021 | ||||
| Series C | Nov 9, 2020 | ||||
Series B | Nov 20, 2019 |
Pinotbio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| BNH INVESTMENT | VC Round |
| I-ON Asset Management | Series C |
| KB Investment | VC Round, Series B |
| Ulmus Investment | Series C |
| Company K Partners | Series A, Seed |
| Stonebridge Ventures | Series B |
| KB Securities | Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 2, 2025
Monthly visitors grew 432% MoM, reaching 1.4K.
- Nov 20, 2019
$8.44M round with participation from Devsisters Ventures and KB Investment.
Recent news
Latest coverage and updates
- is_developingOct 15, 2026
PinotBio, Inc. develops claudin-1-targeting antibody-drug conjugates (ADCs) with Alentis Therapeutics under a research collaboration and licensing agreement for oncology indications on Oct 15th '26.
- is_developingOct 15, 2026
On Oct 15th '26, PinotBio, Inc. enters a research collaboration and licensing agreement with Alentis Therapeutics to develop claudin-1-targeting antibody-drug conjugates for oncology indications.
Pinotbio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Pinotbio's valuation, stock price, and market status.
Is Pinotbio a public or private company?
Pinotbio is a private company.
What is the current stock price of Pinotbio?
Pinotbio is a private company, so its shares have no public market price. Caplight tracks Pinotbio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Pinotbio worth (valuation)?
Pinotbio's valuation is estimated at $79.5M based on funding round data.
Can I buy Pinotbio stock?
Pinotbio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Pinotbio's last funding round?
Pinotbio's most recent funding round was VC Round on October 27, 2025.
Who are the main investors in Pinotbio?
Key investors in Pinotbio include IMM Investment.
Will Pinotbio IPO soon?
No public IPO plans have been announced for Pinotbio.
How can I track Pinotbio secondary market activity?
Caplight tracks bids, offers, and trades in Pinotbio's shares on secondary markets.